Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults

Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of tropical medicine and hygiene 2011-04, Vol.84 (4), p.539-542
Hauptverfasser: LAYEGH, Pouran, RAHSEPAR, Sara, AMIR ALI RAHSEPAR
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 542
container_issue 4
container_start_page 539
container_title The American journal of tropical medicine and hygiene
container_volume 84
creator LAYEGH, Pouran
RAHSEPAR, Sara
AMIR ALI RAHSEPAR
description Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.
doi_str_mv 10.4269/ajtmh.2011.10-0002
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3062445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1014101049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</originalsourceid><addsrcrecordid>eNp9kUFP3DAQhS3UChbKH-CAcqnaSxaP7Tgxh0qrVWmRFvXQVj1aju2wRokDtoPEv8fpbmm59GDZM--bJ48eQmeAl4xwcaHu0rBdEgywBFxijMkBWgCreQmcVW_QYm6VgtP6CB3HeIcxNATgEB0RYDyLfIF-fX-KyQ5OFzf2tp8G522x8skNo3cq2cL5YqWn_FhPSXk7TrHYWBe3g8p6dPGyWG9db4L1xaMNMcsrM_UpvkNvO9VHe7q_T9DPq88_1l_Lzbcv1-vVptQV0FRaoVowwExdMSo62gA1nNeNwoQqk2tq2kbrSujWcNGRujHQtcJiw4w1XUNP0Ked7_3UDtZo61NQvbwPblDhSY7KydeKd1t5Oz5KijlhrMoGH_YGYXyYbExycFHbvt9tKxuOQYBgPJMf_0sCBpYPZiKjZIfqMMYYbPfyIcByzk7-zk7O2c2tOag8dP7vKi8jf8LKwPs9oKJWfReU1y7-5RjmIASlz5AdpSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1014101049</pqid></control><display><type>article</type><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</creator><creatorcontrib>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</creatorcontrib><description>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (&gt; 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2011.10-0002</identifier><identifier>PMID: 21460006</identifier><identifier>CODEN: AJTHAB</identifier><language>eng</language><publisher>Deerfield, IL: American Society of Tropical Medecine and Hygiene</publisher><subject>Adolescent ; Adult ; Age Factors ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiparasitic agents ; Antiprotozoal Agents - administration &amp; dosage ; Antiprotozoal Agents - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Female ; Human protozoal diseases ; Humans ; Infectious diseases ; Leishmaniasis, Cutaneous - drug therapy ; Leshmaniasis ; Male ; Medical sciences ; Medication Adherence ; Meglumine - administration &amp; dosage ; Meglumine - therapeutic use ; Organometallic Compounds - administration &amp; dosage ; Organometallic Compounds - therapeutic use ; Parasitic diseases ; Pharmacology. Drug treatments ; Protozoal diseases ; Young Adult</subject><ispartof>The American journal of tropical medicine and hygiene, 2011-04, Vol.84 (4), p.539-542</ispartof><rights>2015 INIST-CNRS</rights><rights>The American Society of Tropical Medicine and Hygiene 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062445/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062445/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24061993$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21460006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LAYEGH, Pouran</creatorcontrib><creatorcontrib>RAHSEPAR, Sara</creatorcontrib><creatorcontrib>AMIR ALI RAHSEPAR</creatorcontrib><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (&gt; 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiparasitic agents</subject><subject>Antiprotozoal Agents - administration &amp; dosage</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Leishmaniasis, Cutaneous - drug therapy</subject><subject>Leshmaniasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Meglumine - administration &amp; dosage</subject><subject>Meglumine - therapeutic use</subject><subject>Organometallic Compounds - administration &amp; dosage</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Parasitic diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Protozoal diseases</subject><subject>Young Adult</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFP3DAQhS3UChbKH-CAcqnaSxaP7Tgxh0qrVWmRFvXQVj1aju2wRokDtoPEv8fpbmm59GDZM--bJ48eQmeAl4xwcaHu0rBdEgywBFxijMkBWgCreQmcVW_QYm6VgtP6CB3HeIcxNATgEB0RYDyLfIF-fX-KyQ5OFzf2tp8G522x8skNo3cq2cL5YqWn_FhPSXk7TrHYWBe3g8p6dPGyWG9db4L1xaMNMcsrM_UpvkNvO9VHe7q_T9DPq88_1l_Lzbcv1-vVptQV0FRaoVowwExdMSo62gA1nNeNwoQqk2tq2kbrSujWcNGRujHQtcJiw4w1XUNP0Ked7_3UDtZo61NQvbwPblDhSY7KydeKd1t5Oz5KijlhrMoGH_YGYXyYbExycFHbvt9tKxuOQYBgPJMf_0sCBpYPZiKjZIfqMMYYbPfyIcByzk7-zk7O2c2tOag8dP7vKi8jf8LKwPs9oKJWfReU1y7-5RjmIASlz5AdpSw</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>LAYEGH, Pouran</creator><creator>RAHSEPAR, Sara</creator><creator>AMIR ALI RAHSEPAR</creator><general>American Society of Tropical Medecine and Hygiene</general><general>The American Society of Tropical Medicine and Hygiene</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110401</creationdate><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><author>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiparasitic agents</topic><topic>Antiprotozoal Agents - administration &amp; dosage</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Leishmaniasis, Cutaneous - drug therapy</topic><topic>Leshmaniasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Meglumine - administration &amp; dosage</topic><topic>Meglumine - therapeutic use</topic><topic>Organometallic Compounds - administration &amp; dosage</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Parasitic diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Protozoal diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LAYEGH, Pouran</creatorcontrib><creatorcontrib>RAHSEPAR, Sara</creatorcontrib><creatorcontrib>AMIR ALI RAHSEPAR</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LAYEGH, Pouran</au><au>RAHSEPAR, Sara</au><au>AMIR ALI RAHSEPAR</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>84</volume><issue>4</issue><spage>539</spage><epage>542</epage><pages>539-542</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><coden>AJTHAB</coden><abstract>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (&gt; 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</abstract><cop>Deerfield, IL</cop><pub>American Society of Tropical Medecine and Hygiene</pub><pmid>21460006</pmid><doi>10.4269/ajtmh.2011.10-0002</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9637
ispartof The American journal of tropical medicine and hygiene, 2011-04, Vol.84 (4), p.539-542
issn 0002-9637
1476-1645
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3062445
source MEDLINE; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Adolescent
Adult
Age Factors
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiparasitic agents
Antiprotozoal Agents - administration & dosage
Antiprotozoal Agents - therapeutic use
Biological and medical sciences
Child
Child, Preschool
Female
Human protozoal diseases
Humans
Infectious diseases
Leishmaniasis, Cutaneous - drug therapy
Leshmaniasis
Male
Medical sciences
Medication Adherence
Meglumine - administration & dosage
Meglumine - therapeutic use
Organometallic Compounds - administration & dosage
Organometallic Compounds - therapeutic use
Parasitic diseases
Pharmacology. Drug treatments
Protozoal diseases
Young Adult
title Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20Meglumine%20Antimoniate%20in%20Acute%20Cutaneous%20Leishmaniasis:%20Children%20versus%20Adults&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=LAYEGH,%20Pouran&rft.date=2011-04-01&rft.volume=84&rft.issue=4&rft.spage=539&rft.epage=542&rft.pages=539-542&rft.issn=0002-9637&rft.eissn=1476-1645&rft.coden=AJTHAB&rft_id=info:doi/10.4269/ajtmh.2011.10-0002&rft_dat=%3Cproquest_pubme%3E1014101049%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1014101049&rft_id=info:pmid/21460006&rfr_iscdi=true